Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

Bernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...

Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...

Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...

Prioritising efficiency, Indian enterprises are reshaping their spending habits. Non-essential travel and expenses are being minimized, whi...

Suryoday Small Finance Bank reported a strong turnaround in fourth-quarter earnings with improved profitability and higher operating profit...

Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...

Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...

India faces a strong El Niño, threatening below-normal rainfall and impacting agriculture. While rural-linked sectors like two-wheelers and...

Bain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...

Indian markets are set for a dynamic start today. Investors will closely watch the Q4 results from banking giants HDFC Bank and ICICI Bank....

Indian stock markets present attractive opportunities now. Investors with an 18-month outlook should consider deploying funds, especially i...

Lupin shares rose on Friday after the pharma major reported a robust 73% YoY surge in Q2 FY26 PAT to Rs 1,485 crore, driven by strong sales...

Lupin's subsidiary will acquire VISUfarma BV for 190 million euros. This expands Lupin's European business and eye health product range. Th...

"India is critical in shaping Lupin's growth story going forward. This acquisition strengthens our position in the Indian market, where we ...

The drug maker reported negative growth in 2017-18 for the first time in a decade, with net sales dropping to Rs 15,560 crore, a decline of...

Lupin's revenue grew 5% yearon-year to Rs 3,144.9 crore during the December 2014 quarter, much lower than the analysts' expectation of 12-1...